Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.89+0.22 (+1.61%)
Close on Nov 18, 2026Market cap $340.38MP/E –Yield –
Lyell Immunopharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Lyell Immunopharma's revenue for the twelve months ending Jun 30, 2026 was $27.00K, down 55.0% year over year. For fiscal 2025 it was $36.00K, down 41.0% from the year before. The highest annual figure on record is $84.68M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.00K | -41.0% |
| FY2024 | Dec 31, 2024 | $61.00K | -53.1% |
| FY2023 | Dec 31, 2023 | $130.00K | -99.8% |
| FY2022 | Dec 31, 2022 | $84.68M | +695.1% |
| FY2021 | Dec 31, 2021 | $10.65M | +37.3% |
| FY2020 | Dec 31, 2020 | $7.76M | +1080.5% |
| FY2019 | Dec 31, 2019 | $657.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.00K | -50.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.00K | -71.4% |
| Q4 FY2025 | Dec 31, 2025 | $6.00K | -45.5% |
| Q3 FY2025 | Sep 30, 2025 | $15.00K | -55.9% |
| Q2 FY2025 | Jun 30, 2025 | $8.00K | -38.5% |
| Q1 FY2025 | Mar 31, 2025 | $7.00K | +133.3% |
| Q4 FY2024 | Dec 31, 2024 | $11.00K | -15.4% |
| Q3 FY2024 | Sep 30, 2024 | $34.00K | +36.0% |
| Q2 FY2024 | Jun 30, 2024 | $13.00K | -51.9% |
| Q1 FY2024 | Mar 31, 2024 | $3.00K | -95.4% |
| Q4 FY2023 | Dec 31, 2023 | $13.00K | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $25.00K | +733.3% |
| Q2 FY2023 | Jun 30, 2023 | $27.00K | -99.9% |
| Q1 FY2023 | Mar 31, 2023 | $65.00K | -88.2% |
| Q4 FY2022 | Dec 31, 2022 | $48.39M | +1614.6% |
| Q3 FY2022 | Sep 30, 2022 | $3.00K | -99.9% |
| Q2 FY2022 | Jun 30, 2022 | $35.74M | +1260.0% |
| Q1 FY2022 | Mar 31, 2022 | $553.00K | -77.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.82M | +22.1% |
| Q3 FY2021 | Sep 30, 2021 | $2.76M | +157.5% |
| Q2 FY2021 | Jun 30, 2021 | $2.63M | -15.7% |
| Q1 FY2021 | Mar 31, 2021 | $2.45M | – |
| Q4 FY2020 | Dec 31, 2020 | $2.31M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.07M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.12M | – |
See a number that looks wrong?